Walensky RP - Search Results

1

A therapeutic HIV vaccine: how good is good enough?

Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR 3rd, Smith HE, Zhang H, Freedberg KA. Walensky RP, et al. Vaccine. 2004 Sep 28;22(29-30):4044-53. doi: 10.1016/j.vaccine.2004.03.059. Vaccine. 2004. PMID: 15364455

2

AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.

Walensky RP, Paltiel AD, Freedberg KA. Walensky RP, et al. Clin Infect Dis. 2002 Sep 1;35(5):606-10. doi: 10.1086/341903. Epub 2002 Aug 2. Clin Infect Dis. 2002. PMID: 12173137

3

Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy.

Walensky RP, Goldie SJ, Sax PE, Weinstein MC, Paltiel AD, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, Islam R, Freedberg KA. Walensky RP, et al. J Acquir Immune Defic Syndr. 2002 Sep 1;31(1):27-37. doi: 10.1097/00126334-200209010-00004. J Acquir Immune Defic Syndr. 2002. PMID: 12352147

4

Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.

Goldie SJ, Paltiel AD, Weinstein MC, Losina E, Seage GR 3rd, Kimmel AD, Walensky RP, Sax PE, Freedberg KA. Goldie SJ, et al. Among authors: walensky rp. Am J Med. 2003 Dec 1;115(8):632-41. doi: 10.1016/j.amjmed.2003.07.007. Am J Med. 2003. PMID: 14656616

5

Routine human immunodeficiency virus testing: an economic evaluation of current guidelines.

Walensky RP, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, Paltiel AD. Walensky RP, et al. Am J Med. 2005 Mar;118(3):292-300. doi: 10.1016/j.amjmed.2004.07.055. Am J Med. 2005. PMID: 15745728

6

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators. Kimmel AD, et al. Among authors: walensky rp. Antivir Ther. 2005;10(1):41-52. Antivir Ther. 2005. PMID: 15751762

7

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease.

Sax PE, Losina E, Weinstein MC, Paltiel AD, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, Walensky RP. Sax PE, et al. Among authors: walensky rp. J Acquir Immune Defic Syndr. 2005 May 1;39(1):69-77. doi: 10.1097/01.qai.0000160406.08924.a2. J Acquir Immune Defic Syndr. 2005. PMID: 15851916 Clinical Trial.

8

Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral.

Walensky RP, Weinstein MC, Smith HE, Freedberg KA, Paltiel AD. Walensky RP, et al. Med Decis Making. 2005 May-Jun;25(3):321-9. doi: 10.1177/0272989X05276955. Med Decis Making. 2005. PMID: 15951459

9

Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis.

Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, Sadownik SN, Freedberg KA. Sax PE, et al. Among authors: walensky rp. Clin Infect Dis. 2005 Nov 1;41(9):1316-23. doi: 10.1086/496984. Epub 2005 Sep 23. Clin Infect Dis. 2005. PMID: 16206108

10

Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.

Holmes CB, Zheng H, Martinson NA, Freedberg KA, Walensky RP. Holmes CB, et al. Among authors: walensky rp. Clin Infect Dis. 2006 Jun 15;42(12):1772-80. doi: 10.1086/504382. Epub 2006 May 12. Clin Infect Dis. 2006. PMID: 16705586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters